CO2023009368A2 - Cocristal de un inhibidor de cdk - Google Patents

Cocristal de un inhibidor de cdk

Info

Publication number
CO2023009368A2
CO2023009368A2 CONC2023/0009368A CO2023009368A CO2023009368A2 CO 2023009368 A2 CO2023009368 A2 CO 2023009368A2 CO 2023009368 A CO2023009368 A CO 2023009368A CO 2023009368 A2 CO2023009368 A2 CO 2023009368A2
Authority
CO
Colombia
Prior art keywords
cocrystal
cdk inhibitor
relates
cdk7
disorders
Prior art date
Application number
CONC2023/0009368A
Other languages
English (en)
Spanish (es)
Inventor
Uday Bhat
Ranadeep Bokalial
Sangamesh Eshwarappa Badiger
Krishnaswamy Devanathan
Original Assignee
Aurigene Oncology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Oncology Ltd filed Critical Aurigene Oncology Ltd
Publication of CO2023009368A2 publication Critical patent/CO2023009368A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CONC2023/0009368A 2020-12-18 2023-07-14 Cocristal de un inhibidor de cdk CO2023009368A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202041055174 2020-12-18
PCT/IB2021/061895 WO2022130304A1 (en) 2020-12-18 2021-12-17 Cocrystal of a cdk inhibitor

Publications (1)

Publication Number Publication Date
CO2023009368A2 true CO2023009368A2 (es) 2023-09-29

Family

ID=80001496

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0009368A CO2023009368A2 (es) 2020-12-18 2023-07-14 Cocristal de un inhibidor de cdk

Country Status (17)

Country Link
US (1) US20240059669A1 (zh)
EP (1) EP4263534A1 (zh)
JP (1) JP2023554492A (zh)
KR (1) KR20230159363A (zh)
CN (1) CN116685326A (zh)
AU (1) AU2021402415A1 (zh)
CA (1) CA3202198A1 (zh)
CL (1) CL2023001753A1 (zh)
CO (1) CO2023009368A2 (zh)
CR (1) CR20230261A (zh)
DO (1) DOP2023000126A (zh)
EC (1) ECSP23054131A (zh)
IL (1) IL303738A (zh)
MX (1) MX2023007218A (zh)
PE (1) PE20231441A1 (zh)
TW (1) TW202241881A (zh)
WO (1) WO2022130304A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023224961A1 (en) 2022-05-16 2023-11-23 Exelixis, Inc. Cancer therapy using a combination of a cdk7 inhibitor with an oral serd

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016193939A1 (en) 2015-06-04 2016-12-08 Aurigene Discovery Technologies Limited Substituted heterocyclyl derivatives as cdk inhibitors

Also Published As

Publication number Publication date
IL303738A (en) 2023-08-01
WO2022130304A1 (en) 2022-06-23
KR20230159363A (ko) 2023-11-21
CA3202198A1 (en) 2022-06-23
JP2023554492A (ja) 2023-12-27
CR20230261A (es) 2023-10-04
DOP2023000126A (es) 2023-11-30
CN116685326A (zh) 2023-09-01
EP4263534A1 (en) 2023-10-25
US20240059669A1 (en) 2024-02-22
AU2021402415A1 (en) 2023-07-06
PE20231441A1 (es) 2023-09-14
CL2023001753A1 (es) 2024-02-02
TW202241881A (zh) 2022-11-01
ECSP23054131A (es) 2023-09-29
MX2023007218A (es) 2023-07-27

Similar Documents

Publication Publication Date Title
BR112022010383A2 (pt) Compostos tricíclicos substituídos
BR112022012641A2 (pt) Compostos tricíclicos substituídos
CO2023013356A2 (es) Compuestos para la inhibición de nlrp3 y usos de estos
MD3601283T2 (ro) Compus inhibitor JAK pe bază de imidazo-piperidină fuzionată
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
BR112021020637A2 (pt) Derivados de tetra-hidro-1h-ciclopenta[cd]indeno como inibidores de fator -2(alfa) induzível por hipóxia
CR20190124A (es) Inhibidores de ssao de aminopirimidina
WO2018198077A3 (en) 6-6 FUSIONED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS INHIBITORS OF LATS
NO20076093L (no) Substituerte amidderivater som proteinkinaseinhibitorer
NO20033181L (no) Substituerte alkylaminderivater og fremgangsmåter for anvendelse
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
SG10201902206QA (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
CU24671B1 (es) Compuesto de pirimidina inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación
DOP2021000077A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
ECSP23054131A (es) Cocristal de un inhibidor de cdk
CO2019010559A2 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos
MX2022015531A (es) Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo.
BRPI0509653A (pt) inibidores cinesina mitótica
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
BR112022010181A2 (pt) Composto tri-heterocíclico como inibidor de jak e uso do mesmo
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы